The Pharma Data

JANUARY 10, 2021

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D., In July 2020, the U.S.

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

OCTOBER 27, 2020

Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.

Development 52

Development Protein Manufacturing Medicine 52

The Pharma Data

NOVEMBER 18, 2020

Trial to be paused pending analysis of data and evaluation of plans for further development. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Trials 40

Trials Production Development Marketing 40

The Pharma Data

NOVEMBER 22, 2020

MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. Upon option exercise, Novartis would be responsible for all further development and commercialization activities. Chief Medical Officer of Molecular Partners.

Trials 40

Trials Protein Clinical Trials Clinical Trials 40